Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer
Latest Information Update: 06 Jan 2020
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary) ; Capecitabine
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 06 Jan 2020 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified January 2018).
- 28 Mar 2017 New trial record